WO2017217747A1 - Composition for treating, preventing or reducing edema - Google Patents

Composition for treating, preventing or reducing edema Download PDF

Info

Publication number
WO2017217747A1
WO2017217747A1 PCT/KR2017/006160 KR2017006160W WO2017217747A1 WO 2017217747 A1 WO2017217747 A1 WO 2017217747A1 KR 2017006160 W KR2017006160 W KR 2017006160W WO 2017217747 A1 WO2017217747 A1 WO 2017217747A1
Authority
WO
WIPO (PCT)
Prior art keywords
lymphedema
extract
monosperma
composition
buta
Prior art date
Application number
PCT/KR2017/006160
Other languages
French (fr)
Korean (ko)
Inventor
구진모
이석찬
박계원
이정헌
이석오
홍성수
노강산
송노준
Original Assignee
재단법인 경기도경제과학진흥원
성균관대학교산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 재단법인 경기도경제과학진흥원, 성균관대학교산학협력단 filed Critical 재단법인 경기도경제과학진흥원
Publication of WO2017217747A1 publication Critical patent/WO2017217747A1/en

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health

Definitions

  • the present invention relates to a composition comprising an extract or fraction extract of buta monosperma as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition for treating or preventing lymphedema, or a food composition for improving or preventing lymphedema, comprising an extract or fraction extract of buta monosperma as an active ingredient.
  • Buttea monosperma is a scientific name for plants native to India, the subcontinent of India, Bangladesh, Nepal, Sri Lanka, and Southeast Asia. It grows slowly and grows up to a height of about 10 to 15 m, and the petals of orange to red color show the parrot's beak shape.
  • the butae monosperma is known to exhibit a variety of efficacy.
  • US Publication No. US 2006/0013782 discloses that the active extract of butane monosperma has a cosmetic effect of improving appearance through lightening of hair, skin, lips and nails.
  • Chinese Patent Publication No. 101287481 discloses that extracts of butane monosperma exhibit therapeutic efficacy of hepatocellular carcinoma.
  • the lymph edema can be divided into primary lymphedema caused by congenital genetic abnormality and secondary lymphedema that is acquired by surgery or radiation therapy.
  • the secondary lymphedema is very often seen as a sequelae after surgical treatment and / or radiation treatment for breast cancer, uterine cancer.
  • breast or uterine cancer patients undergoing surgery or radiation therapy are considered potential secondary lymphedema patients.
  • the lymph edema can be divided into stages 0, 1, 2, 3 according to the degree.
  • Stage 0 is the incubation status of lymphatic fluid is reduced but there is no clinical symptoms
  • Stage 1 refers to the condition that the edema is visible and long-term when the skin is pressed
  • stage 2 is the accumulation of protein in the tissues, fibrosis The state does not enter even when the skin is pressed by the season
  • the third stage refers to a state in which the skin is excessively inflated and the function of the skin is lost.
  • lymphedema is caused by problems with the circulation of the lymphatic system and swelling. Because it is another disease, it clearly states that there is an independent need for appropriate management and treatment methods for lymphedema.
  • the treatment of secondary lymphedema is said to be the most effective treatment of multiple lymphedema recommended by the World Lymph Association.
  • the combined lymphedema therapy refers to lymph massage, compression therapy, exercise and skin care.
  • complex lymphedema therapy not only differs in efficacy depending on the degree of proficiency of the patient, the number and intervals of the therapy, but also includes the problem that it takes a long time to cure and nevertheless difficult to cure. have.
  • lymphedema and other separate therapies such as body metabolism and kidney problems are required for lymphedema
  • therapies such as lymph massage, compression therapy, exercise, and skin care, which are commonly used, It cannot be a fundamental and efficient solution. Therefore, there is still a need in the art to develop new compositions that can fundamentally treat or improve lymphedema in a short time and can prevent the development of lymphedema in advance.
  • the inventors conducted experiments using various plant species for the purpose of essentially treating, preventing or improving lymphedema. As a result, it has been surprisingly demonstrated that the above object can be effectively achieved by extracts or fractions of butane monosperma, thus leading to the present invention.
  • the present invention provides a composition comprising an extract or fraction of buta monosperma that can significantly treat, prevent or ameliorate lymphedema.
  • buta monosperma may be used without limitation, such as cultivated, harvested or commercially available.
  • extract refers to a preparation obtained by extracting a crude drug with an appropriate extraction solvent and evaporating the extraction solvent, which includes the extract obtained by the extraction treatment, the dilution or concentrate of the extract, and the extract It is interpreted that the obtained dried material, these crude agents or purified products, or fractions are included.
  • a monosperma extract according to the present invention can be prepared using a common extraction method known in the art, for example, hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, ultrasonic extraction, enzyme extraction, or Methods such as acid treatment extraction can be used.
  • enzyme extraction or acid treatment extraction methods are used.
  • the extract or fraction of butane monosperma is, for example, a solvent selected from the group consisting of water, ethyl acetate, acetone, C 1-4 alcohol (eg, ethanol, methanol, etc.), chloroform, dichloromethane and mixtures thereof. Can be obtained.
  • the concentration of the C 1-4 alcohol is preferably 10% to 90%, but is not limited thereto.
  • the extract or fraction is obtained from the group consisting of leaves, branches, stems, flowers, roots, bark and mixtures thereof of buta monosperma.
  • the extract or fraction is obtained from the flower of buta monosperma.
  • the lymphedema is secondary lymphedema caused after cancer surgery or radiation treatment.
  • treatment refers to any action by which administration of a composition according to the present invention improves or cures a disease or condition.
  • prevention refers to any action by which administration of a composition according to the present invention inhibits or delays a disease or condition.
  • improvement refers to any action by which administration of a composition according to the present invention reduces, improves, or delays the progress of a disease or condition.
  • the content of the extract or fraction of buta monosperma which is included as an active ingredient in the composition according to the present invention, may vary depending on the age, sex, weight and health of the subject, the severity of lymphedema, the time of onset, the duration of treatment, the route of administration, and the like. Factors may be considered and appropriately selected by those skilled in the art or skilled practitioner in view of the factors.
  • the content of buta monosperma extract may be 0.001 to 100% by weight based on the total weight of the cosmetic composition.
  • the daily dosage of the composition according to the present invention may be determined by those skilled in the art in consideration of various factors such as the age, sex, weight and health of the subject, the severity of lymphedema, the time of onset, the duration of treatment, the route of administration and the like. The doctor can make the appropriate choice.
  • the daily dosage of a composition according to the invention may be an amount of 500 mg per kg of body weight of the subject.
  • the daily dose may be administered to a subject once or divided into several times a day.
  • the term "subject" refers to an animal including a human, a mammal.
  • the subject is a human.
  • the subject is a patient already suffering from lymphedema or a patient at high or probable risk of developing lymphedema.
  • compositions according to the invention can be administered to a subject by a variety of pharmaceutically or foodologically acceptable routes.
  • it may be administered by oral, subcutaneous or intravenous injection, but is not limited to this route of administration.
  • the composition according to the invention is provided in the form of a food or food supplement, it is usually administered orally to the subject.
  • composition according to the invention can be formulated in various formulations, oral and parenteral, without being limited to particular formulations.
  • the active ingredient according to the present invention may be contained in a unit dose in the formulation, or may be divided into aliquots.
  • Solid form preparations for oral administration can be, for example, tablets, pills, powders, granules, capsules and the like, which include one or more excipients such as starch, calcium carbonate, sucrose, Lactose or gelatin and the like.
  • Liquid preparations for oral administration may be, for example, suspensions, solutions, emulsions and syrups, and various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc., in addition to commonly used diluents such as water and liquid paraffin. May be included.
  • Formulations for parenteral administration can be, for example, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, suppositories, and the like.
  • suspending solvent propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used.
  • food additives widely used in the art such as flavoring agents, vitamins and the like may be further included.
  • the composition of the present invention so long as the other active ingredients known in the art to exhibit the effect of treating, preventing or improving lymphedema are not inhibiting the effects or causing side effects of the active ingredient according to the present invention. May be included in addition to.
  • the composition according to the invention can significantly reduce the size of lymphedema. Moreover, because the rate of reducing the size of lymphedema is fast, the effect can be achieved in a significantly shorter time than conventionally used therapies for treating or improving lymphedema. In addition, the composition according to the present invention exhibits the effect of inhibiting, blocking and preventing the production or expansion of lymphedema.
  • the extract or fraction of buta monosperma which is included as an active ingredient in the composition according to the present invention, is derived from natural products and has no side effects or adverse effects on the subject.
  • the composition according to the present invention can exhibit a good treatment and improvement effect to a desired degree in a short time for a subject already suffering from lymphedema.
  • it may have an effect of preventing lymphedema in advance in subjects potentially possessing the possibility of having lymphedema (eg, patients undergoing cancer surgery and / or radiation therapy), thereby inciting the incidence of lymphedema. Significantly lower.
  • composition of the present invention may be provided in the form of a pharmaceutical, or alternatively, in the form of a functional food or a food supplement.
  • Figure 1 is a graph showing the change in the size of lymph edema when the lymphedema-induced mouse was treated with an extract of butane monosperma
  • Figure 2 is a graph divided by time.
  • Figure 3 is a photograph taken with a camera the size of lymph edema when the lymphedema-induced mouse treated with an extract of buta monosperma. Where day 0 is the date when the surgical operation was performed to induce lymphedema.
  • FIG. 4 is a graph showing the size of lymph edema in percentage (%) based on the largest value of lymph edema (day 2).
  • the insoluble solids were removed through a filtration process to obtain a filtrate.
  • the filtrate was concentrated under reduced pressure to give a solid extract.
  • the resulting solid extract was partitioned into an organic layer and an aqueous layer using an organic solvent, and the organic layer was concentrated under reduced pressure to generate a fraction.
  • the organic solvent was ethyl acetate, chloroform or dichloromethane.
  • the acid catalyst is 10% 1N HCl, 10% 3N HCl, 10% 6N HCl, 10% CH 3 SO 4 H, 1% H 2 SO 4 , 2.5% H 2 SO 4 , 5% H 2 SO 4 or 10% H 2 SO 4 was used.
  • the insoluble solids were removed through a filtration process to obtain a filtrate.
  • the filtrate was concentrated under reduced pressure to give a solid extract.
  • the resulting solid extract was partitioned into an organic layer and an aqueous layer using an organic solvent, and the organic layer was concentrated under reduced pressure to generate a fraction.
  • the organic solvent was ethyl acetate, chloroform or dichloromethane.
  • mice originating from Charles River Laboratories (Wilmington, Massachusetts) were used.
  • 3 ⁇ l of 2% methylene blue solution for staining lymph nodes and lymphatic vessels was injected into the inferior right leg, and the dye injection site was massaged for 3 minutes to allow the dye to spread well along the lymphatic vessels.
  • the right groin was incised and opened minimally to minimize the inflamed area due to lymph node resection of the groin and blockage of the lymphatic vessel of the thigh. Subsequently, superficial inguinal nodes, popliteal nodes, and deep inguinal nodes stained with methylene blue were sequentially removed, and lymphatic vessels stained on the right lower thigh were blocked using a pharynx, and then sutured.
  • mice were divided into three groups: normal (2), control (4) and experimental (3).
  • the normal group is a group without surgery on the mice.
  • the experimental group orally administered the ethyl acetate fraction of buta monosperma obtained in Example 1-2 at an amount of 500 mg / kg (mouse of mouse) daily for 7 days, and then surgically performed the right side of the mouse. Lymphedema was induced in the lower extremities.
  • the control group was orally administered with ethanol buffer and distilled water for 7 days, and then surgically induced lymphedema in the right lower extremity of the mouse.
  • the day of surgery was set to 0 day, the body weight and feed intake of the mice were measured once daily, the size of lymph edema was measured once every two days.
  • the experimental results are as follows.
  • mice As measured for 15 days from the day of surgery, the body weight (g) and feed intake (g) of the mice did not show a significant difference between the control group and the experimental group.
  • Figs. 1 and 2 The size of lymph edema is shown graphically in Figs. 1 and 2 showing the mean area (in mm 2 ) of lymph edema in experimental and control mice.
  • photos of each group taken on day 0, day 2, day 4 and day 6 are shown in FIG.
  • Lymphedema was the largest on day 2, the second day after surgery in both control and experimental groups. Thereafter, the size of lymphedema decreased in both control and experimental groups.
  • the lymphedema of the experimental group was significantly smaller than that of the control group. This is a result of oral administration of an extract or fraction of butane monosperma for 7 days before lymphedema develops, suggesting that the composition according to the present invention has the effect of inhibiting and preventing the formation of lymphedema in advance. To prove.
  • the size of lymph edema was determined based on the largest value, and the rate of lymph edema reduction with time was compared. As a result, it was confirmed that the size of lymph edema decreases much faster in the experimental group than in the control group (see FIG. 4).

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

The present invention relates to a pharmaceutical composition for treating or preventing lymphedema, the composition containing a Butea monosperma extract or fractionated extract as an active ingredient. In addition, the present invention relates to a food composition for reducing or preventing lymphedema, the composition containing a Butea monosperma extract or fractionated extract as an active ingredient.

Description

부종의 치료, 예방 또는 개선용 조성물Compositions for the treatment, prevention or improvement of edema
본 발명은 부테아 모노스페르마의 추출물 또는 분획추출물을 유효성분으로 포함하는 조성물에 관한 것이다. 보다 구체적으로, 본 발명은 부테아 모노스페르마의 추출물 또는 분획추출물을 유효성분으로 포함하는 림프부종의 치료 또는 예방용 약학 조성물, 또는 림프부종의 개선 또는 예방용 식품 조성물에 관한 것이다.The present invention relates to a composition comprising an extract or fraction extract of buta monosperma as an active ingredient. More specifically, the present invention relates to a pharmaceutical composition for treating or preventing lymphedema, or a food composition for improving or preventing lymphedema, comprising an extract or fraction extract of buta monosperma as an active ingredient.
부테아 모노스페르마(butea monosperma)는 인도를 비롯하여 방글라데시, 네팔, 스리랑카 등 인도아대륙과 동남아시아 지역을 원산지로 하는 식물의 학명이다. 천천히 성장하여 약 10 내지 15 m의 높이까지 자라며, 주황색 내지 붉은색을 띄는 꽃잎은 그 모양이 앵무새의 부리 형상을 나타낸다.Buttea monosperma is a scientific name for plants native to India, the subcontinent of India, Bangladesh, Nepal, Sri Lanka, and Southeast Asia. It grows slowly and grows up to a height of about 10 to 15 m, and the petals of orange to red color show the parrot's beak shape.
상기 부테아 모노스페르마는 다양한 효능을 나타내는 것으로 알려져 있다. 예를 들어, 미국공개공보 US 2006/0013782는 부테아 모노스페르마의 활성 추출물이 머리카락, 피부, 입술, 손톱의 라이트닝을 통해 외관을 개선시키는 미용 효과가 있다고 개시하고 있다. 또한, 중국공개공보 CN 101287481은 부테아 모노스페르마의 추출물이 간세포암의 치료 효능을 나타낸다고 개시하고 있다.The butae monosperma is known to exhibit a variety of efficacy. For example, US Publication No. US 2006/0013782 discloses that the active extract of butane monosperma has a cosmetic effect of improving appearance through lightening of hair, skin, lips and nails. In addition, Chinese Patent Publication No. 101287481 discloses that extracts of butane monosperma exhibit therapeutic efficacy of hepatocellular carcinoma.
그러나, 부테아 모노스페르마의 추출물 또는 분획물과 림프부종(lymphedema)의 관계에 대해서는 현재까지 연구된 바 없으며 어디에도 개시되어 있지 않다.However, the relationship between extracts or fractions of buta monosperma and lymphedema has not been studied to date and is not disclosed anywhere.
상기 림프부종은 크게 선천적인 유전적 이상으로 인해 발생하는 일차성 림프부종과 수술, 방사선 치료 등으로 인해 후천적으로 발생하는 이차성 림프부종으로 나눌 수 있다. 특히, 상기 이차성 림프부종은 유방암, 자궁암에 대한 수술 치료 및/또는 방사선 치료 후의 후유증으로서 나타나는 경우가 매우 많다. 따라서, 수술이나 방사선 치료를 받은 유방암 또는 자궁암 환자는 잠재적인 이차성 림프부종 환자로 여겨진다.The lymph edema can be divided into primary lymphedema caused by congenital genetic abnormality and secondary lymphedema that is acquired by surgery or radiation therapy. In particular, the secondary lymphedema is very often seen as a sequelae after surgical treatment and / or radiation treatment for breast cancer, uterine cancer. Thus, breast or uterine cancer patients undergoing surgery or radiation therapy are considered potential secondary lymphedema patients.
또한, 상기 림프부종은 그 정도에 따라 0기, 1기, 2기, 3기로 나눌 수 있다. 0기는 잠복기로 림프액 이동 능력은 저하되어 있지만 임상증상이 없는 상태를 말하고, 1기는 부종이 눈에 띄게 보이며 피부를 눌렀을 때 장기간 들어가 있는 상태를 말하고, 2기는 조직에 단백질이 축적되어 섬유경화증이 오는 시기로 피부를 눌러도 들어가지 않는 상태를 말하고, 3기는 피부가 과다하게 팽창되고 피부의 기능을 상실한 상태를 말한다.In addition, the lymph edema can be divided into stages 0, 1, 2, 3 according to the degree. Stage 0 is the incubation status of lymphatic fluid is reduced but there is no clinical symptoms, Stage 1 refers to the condition that the edema is visible and long-term when the skin is pressed, and stage 2 is the accumulation of protein in the tissues, fibrosis The state does not enter even when the skin is pressed by the season, and the third stage refers to a state in which the skin is excessively inflated and the function of the skin is lost.
이와 관련하여, 보건복지부에서 주관하고 국립암센터에서 운영하는 국가암정보센터에 따르면, 림프부종은 림프계 순환의 문제로 발생되어 붓는 증상으로 몸의 신진대사나 신장의 문제 등으로 나타나는 부종의 증상과는 다른 질환이기 때문에, 림프부종에 적합한 관리 및 치료 방법이 독립적으로 필요하다는 점을 명시하고 있다.In this regard, according to the National Cancer Information Center, which is managed by the Ministry of Health and Welfare and operated by the National Cancer Center, lymphedema is caused by problems with the circulation of the lymphatic system and swelling. Because it is another disease, it clearly states that there is an independent need for appropriate management and treatment methods for lymphedema.
또한, 국민건강보험공단에 따르면, 이차성 림프부종의 치료법은 세계림프협회에서 추천하는 복합적 림프부종 요법이 가장 효과적이라고 언급하고 있다. 여기서, 상기 복합적 림프부종 요법은 림프마사지, 압박치료, 운동 및 피부관리를 가리킨다. 그러나, 이와 같은 복합적 림프부종 요법은 환자의 숙달 정도, 요법의 수행 횟수 및 간격에 따라 그 효능이 상이하게 나타날 뿐만 아니라, 치유에 장기간이 소요된다는 문제점과 그럼에도 불구하고 완치가 어렵다는 문제점을 함께 내포하고 있다. In addition, according to the National Health Insurance Corporation, the treatment of secondary lymphedema is said to be the most effective treatment of multiple lymphedema recommended by the World Lymph Association. Here, the combined lymphedema therapy refers to lymph massage, compression therapy, exercise and skin care. However, such complex lymphedema therapy not only differs in efficacy depending on the degree of proficiency of the patient, the number and intervals of the therapy, but also includes the problem that it takes a long time to cure and nevertheless difficult to cure. have.
이와 같이 몸의 신진대사나 신장의 문제 등으로 나타나는 부종과 다른 별개의 요법이 림프부종에 대해 요구됨에도 불구하고, 지금까지 통상적으로 이용되고 있는 림프마사지, 압박치료, 운동, 피부관리 등과 같은 요법들은 근본적이고 효율적인 방안이 될 수 없다. 따라서, 림프부종을 단시간내에 근본적으로 치료 또는 개선할 수 있고 림프부종의 발생을 미연에 방지할 수 있는 새로운 조성물이 개발될 필요성이 당업계에 여전히 존재한다.Although edema and other separate therapies such as body metabolism and kidney problems are required for lymphedema, therapies such as lymph massage, compression therapy, exercise, and skin care, which are commonly used, It cannot be a fundamental and efficient solution. Therefore, there is still a need in the art to develop new compositions that can fundamentally treat or improve lymphedema in a short time and can prevent the development of lymphedema in advance.
본 발명자들은 림프부종을 근본적으로 치료, 예방 또는 개선하기 위한 목적으로 다양한 식물종들을 이용하여 실험을 수행하였다. 그 결과, 놀랍게도 부테아 모노스페르마의 추출물 또는 분획물에 의해 상기 목적이 효과적으로 달성될 수 있다는 점을 입증하여, 본 발명에 이르게 되었다.The inventors conducted experiments using various plant species for the purpose of essentially treating, preventing or improving lymphedema. As a result, it has been surprisingly demonstrated that the above object can be effectively achieved by extracts or fractions of butane monosperma, thus leading to the present invention.
본 발명은 림프부종을 유의적으로 치료, 예방 또는 개선할 수 있는 부테아 모노스페르마의 추출물 또는 분획물을 포함하는 조성물을 제공한다.The present invention provides a composition comprising an extract or fraction of buta monosperma that can significantly treat, prevent or ameliorate lymphedema.
본 발명에 따른 조성물에 있어서, 부테아 모노스페르마는 재배한 것, 채취한 것 또는 시판되는 것 등이 제한 없이 사용될 수 있다.In the composition according to the present invention, buta monosperma may be used without limitation, such as cultivated, harvested or commercially available.
본 발명에 사용되는 용어 "추출물"은 생약을 적절한 추출용매로 추출하고 추출용매를 증발시켜 농축한 제제를 의미하는 것으로, 여기에는 추출처리에 의해 얻어지는 추출액, 추출액의 희석액 또는 농축액, 추출액을 건조하여 얻어지는 건조물, 이들의 조정제물 또는 정제물, 또는 분획물이 포함되는 것으로 해석된다. 본 발명에 따른 부테아 모노스페르마 추출물은 당업계에 공지된 일반적인 추출방법을 이용하여 제조할 수 있으며, 예를 들어 열탕 추출, 열수 추출, 냉침 추출, 환류 냉각 추출, 초음파 추출, 효소 추출, 또는 산처리 추출 등의 방법을 사용할 수 있다. 바람직하게는, 효소 추출 또는 산처리 추출 방법이 사용된다.The term "extract" as used in the present invention refers to a preparation obtained by extracting a crude drug with an appropriate extraction solvent and evaporating the extraction solvent, which includes the extract obtained by the extraction treatment, the dilution or concentrate of the extract, and the extract It is interpreted that the obtained dried material, these crude agents or purified products, or fractions are included. Buta monosperma extract according to the present invention can be prepared using a common extraction method known in the art, for example, hot water extraction, hot water extraction, cold extraction, reflux cooling extraction, ultrasonic extraction, enzyme extraction, or Methods such as acid treatment extraction can be used. Preferably, enzyme extraction or acid treatment extraction methods are used.
상기 부테아 모노스페르마의 추출물 또는 분획물은 예를 들어 물, 에틸아세테이트, 아세톤, C1-4 알코올(예컨대, 에탄올, 메탄올 등), 클로로포름, 디클로로메탄 및 이들의 혼합물로 이루어진 군에서 선택된 용매를 이용하여 수득될 수 있다. 상기 C1-4 알코올의 농도는 10% 내지 90%가 바람직하지만 이에 한정되는 것은 아니다.The extract or fraction of butane monosperma is, for example, a solvent selected from the group consisting of water, ethyl acetate, acetone, C 1-4 alcohol (eg, ethanol, methanol, etc.), chloroform, dichloromethane and mixtures thereof. Can be obtained. The concentration of the C 1-4 alcohol is preferably 10% to 90%, but is not limited thereto.
일 구현예에 따르면, 상기 추출물 또는 분획물은 부테아 모노스페르마의 잎, 가지, 줄기, 꽃, 뿌리, 나무껍질 및 이들의 혼합물로 이루어진 군으로부터 수득된 것이다. 바람직하게는, 상기 추출물 또는 분획물은 부테아 모노스페르마의 꽃으로부터 수득된 것이다.According to one embodiment, the extract or fraction is obtained from the group consisting of leaves, branches, stems, flowers, roots, bark and mixtures thereof of buta monosperma. Preferably, the extract or fraction is obtained from the flower of buta monosperma.
일 구현예에 따르면, 상기 림프부종은 암 수술 또는 방사선 치료 이후에 유발된 이차성 림프부종이다.According to one embodiment, the lymphedema is secondary lymphedema caused after cancer surgery or radiation treatment.
본 발명에서 사용되는 용어 "치료"는 본 발명에 따른 조성물의 투여로 질환 또는 이상 증세가 호전되거나 완치되는 모든 행위를 의미한다. 본 발명에서 사용되는 용어 "예방"은 본 발명에 따른 조성물의 투여로 질환 또는 이상 증세가 억제 또는 지연되는 모든 행위를 의미한다. 본 발명에서 사용되는 용어 "개선"은 본 발명에 따른 조성물의 투여로 질환 또는 이상 증세의 정도가 감소되거나 호전되거나 진행이 지연되는 모든 행위를 의미한다.As used herein, the term "treatment" refers to any action by which administration of a composition according to the present invention improves or cures a disease or condition. As used herein, the term "prevention" refers to any action by which administration of a composition according to the present invention inhibits or delays a disease or condition. As used herein, the term "improvement" refers to any action by which administration of a composition according to the present invention reduces, improves, or delays the progress of a disease or condition.
본 발명에 따른 조성물에 유효성분으로 포함되는 부테아 모노스페르마의 추출물 또는 분획물의 함량은 대상체의 연령, 성별, 체중 및 건강상태, 림프부종의 중증도, 발병 시점, 치료 기간, 투여 경로 등의 다양한 인자들을 고려하여 당업계의 통상의 기술자 또는 숙련된 의사가 적절하게 선택할 수 있다. 예를 들어, 부테아 모노스페르마 추출물의 함량은 화장료 조성물 전체 중량 대비 0.001 내지 100 중량%일 수 있다.The content of the extract or fraction of buta monosperma, which is included as an active ingredient in the composition according to the present invention, may vary depending on the age, sex, weight and health of the subject, the severity of lymphedema, the time of onset, the duration of treatment, the route of administration, and the like. Factors may be considered and appropriately selected by those skilled in the art or skilled practitioner in view of the factors. For example, the content of buta monosperma extract may be 0.001 to 100% by weight based on the total weight of the cosmetic composition.
본 발명에 따른 조성물의 일일 투여량은 대상체의 연령, 성별, 체중 및 건강상태, 림프부종의 중증도, 발병 시점, 치료 기간, 투여 경로 등의 다양한 인자들을 고려하여 당업계의 통상의 기술자 또는 숙련된 의사가 적절하게 선택할 수 있다. 예를 들어, 본 발명에 따른 조성물의 일일 투여량은 대상체의 체중 kg 당 500 mg의 양이 될 수 있다. 상기 일일 투여량은 하루에 1회 또는 수회로 나누어 대상체에게 투여하는 것도 가능하다.The daily dosage of the composition according to the present invention may be determined by those skilled in the art in consideration of various factors such as the age, sex, weight and health of the subject, the severity of lymphedema, the time of onset, the duration of treatment, the route of administration and the like. The doctor can make the appropriate choice. For example, the daily dosage of a composition according to the invention may be an amount of 500 mg per kg of body weight of the subject. The daily dose may be administered to a subject once or divided into several times a day.
본 발명에서, "대상체"라는 용어는 인간, 포유류를 포함한 동물을 나타낸다. 바람직하게는, 상기 대상체는 인간이다. 특히, 상기 대상체는 림프부종을 이미 앓고 있는 환자, 또는 림프부종에 걸릴 위험이 높거나 가능성이 있는 환자이다.In the present invention, the term "subject" refers to an animal including a human, a mammal. Preferably, the subject is a human. In particular, the subject is a patient already suffering from lymphedema or a patient at high or probable risk of developing lymphedema.
본 발명에 따른 약학 조성물은 약학적으로 또는 식품학적으로 허용되는 다양한 경로로 대상체에게 투여될 수 있다. 예를 들어, 경구, 피하 또는 정맥 주사에 의해 투여될 수 있지만, 이러한 투여 경로에 한정되는 것은 아니다. 본 발명에 따른 조성물이 식품 또는 식품보충제의 형태로 제공되는 경우, 대상체에게 경구로 투여되는 것이 일반적이다.The pharmaceutical compositions according to the invention can be administered to a subject by a variety of pharmaceutically or foodologically acceptable routes. For example, it may be administered by oral, subcutaneous or intravenous injection, but is not limited to this route of administration. When the composition according to the invention is provided in the form of a food or food supplement, it is usually administered orally to the subject.
본 발명에 따른 조성물은 특정 제형에 한정됨이 없이, 경구 및 비경구의 여러가지 제형들로 제제화될 수 있다. 이때, 본 발명에 따른 유효성분은 제형 내에 단위 용량으로 함유될 수도 있고, 분취량으로 나뉘어 함유될 수도 있다. 본 발명에 따른 조성물을 제제화하는 경우, 약학적으로 또는 식품학적으로 허용되는 통상의 가소제, 부형제, 붕해제, 충진제, 증량제, 결합제, 활택제, 착색제, 습윤제, 감미제, 방향제, 보존제, 계면활성제, 희석제, 항산화제 등의 다양한 첨가제들을 필요에 따라 추가로 포함할 수 있다. 경구 투여를 위한 고형제제는 예를 들어 정제, 환제, 산제, 과립제, 캡슐제 등일 수 있으며, 여기에는 부테아 모노스페르마 추출물 또는 분획물 외에 하나 이상의 부형제, 예를 들어 전분, 탄산칼슘, 수크로스, 락토오스 또는 젤라틴 등이 포함될 수 있다. 경구 투여를 위한 액상제제는 예를 들어 현탁제, 내용액제, 유제 및 시럽제 등일 수 있으며, 여기에는 통상적으로 사용되는 희석제인 물, 리퀴드 파라핀 외에 여러가지 부형제들, 예컨대 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 비경구 투여를 위한 제제는 예를 들어 멸균된 수용액, 비수용성제, 현탁용제, 유제, 동결건조제제, 좌제 등일 수 있다. 상기 현탁용제로서 프로필렌 글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사가능한 에스테르 등이 사용될 수 있다. 또한, 본 발명에 따른 조성물이 식품으로서 사용되는 경우에는 향미제, 비타민 등과 같이 당업계에서 널리 사용되는 식품 첨가제가 추가로 포함될 수 있다.The composition according to the invention can be formulated in various formulations, oral and parenteral, without being limited to particular formulations. At this time, the active ingredient according to the present invention may be contained in a unit dose in the formulation, or may be divided into aliquots. When formulating a composition according to the invention, conventional plasticizers, excipients, disintegrants, fillers, extenders, binders, glidants, colorants, wetting agents, sweeteners, fragrances, preservatives, surfactants, Various additives, such as a diluent and antioxidant, may be further included as needed. Solid form preparations for oral administration can be, for example, tablets, pills, powders, granules, capsules and the like, which include one or more excipients such as starch, calcium carbonate, sucrose, Lactose or gelatin and the like. Liquid preparations for oral administration may be, for example, suspensions, solutions, emulsions and syrups, and various excipients such as wetting agents, sweeteners, fragrances, preservatives, etc., in addition to commonly used diluents such as water and liquid paraffin. May be included. Formulations for parenteral administration can be, for example, sterile aqueous solutions, non-aqueous solutions, suspensions, emulsions, lyophilized preparations, suppositories, and the like. As the suspending solvent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like can be used. In addition, when the composition according to the present invention is used as a food, food additives widely used in the art such as flavoring agents, vitamins and the like may be further included.
선택적인 일 구현예에 따르면, 림프부종의 치료, 예방 또는 개선 효과를 나타내는 것으로 당업계에 알려져 있는 다른 활성성분들이 본 발명에 따른 유효성분의 효과를 저해하거나 부작용을 일으키지 않는 한, 본 발명의 조성물에 추가로 포함될 수 있다.According to an optional embodiment, the composition of the present invention, so long as the other active ingredients known in the art to exhibit the effect of treating, preventing or improving lymphedema are not inhibiting the effects or causing side effects of the active ingredient according to the present invention. May be included in addition to.
본 발명에 대해서는 하기의 실시예와 본 명세서에 첨부된 도면에 기초하여 보다 상세하게 설명될 것이나, 이는 본 발명의 권리범위를 제한하려는 것이 아니다. 또한, 당업계에서 통상의 지식을 가진 자라면 본 발명의 취지를 해하지 않는 범위 내에서 본 발명에 대해 다양한 변형 및 수정을 가할 수 있을 것이다.The present invention will be described in more detail based on the following examples and drawings appended hereto, but this is not intended to limit the scope of the invention. In addition, those skilled in the art will be able to make various changes and modifications to the present invention without departing from the spirit of the present invention.
본 발명에 따른 조성물은 림프부종의 크기를 유의적으로 감소시킬 수 있다. 더욱이, 림프부종의 크기를 감소시키는 속도가 빠르므로, 림프부종을 치료하거나 개선하기 위해 종래에 사용되던 요법에 비해 현저하게 더 짧은 시간내에 그 효과를 얻을 수 있다. 또한, 본 발명에 따른 조성물은 림프부종의 생성 또는 확장을 억제, 차단, 예방하는 효과를 나타낸다.The composition according to the invention can significantly reduce the size of lymphedema. Moreover, because the rate of reducing the size of lymphedema is fast, the effect can be achieved in a significantly shorter time than conventionally used therapies for treating or improving lymphedema. In addition, the composition according to the present invention exhibits the effect of inhibiting, blocking and preventing the production or expansion of lymphedema.
뿐만 아니라, 본 발명에 따른 조성물에 유효성분으로서 포함되는 부테아 모노스페르마의 추출물 또는 분획물은 천연물에서 유래된 것으로 대상체에게 부작용 또는 역효과가 없다.In addition, the extract or fraction of buta monosperma, which is included as an active ingredient in the composition according to the present invention, is derived from natural products and has no side effects or adverse effects on the subject.
따라서, 본 발명에 따른 조성물은 림프부종을 이미 앓고 있는 대상체에 대해서는 단시간내에 원하는 정도로 우수한 치료 및 개선 효과를 나타낼 수 있다. 또한, 림프부종을 앓을 가능성을 잠재적으로 보유하고 있는 대상체(예컨대, 암 수술을 받거나 및/또는 방사선 치료를 받은 환자)에 대해서는 림프부종을 미리 예방하는 효과를 나타낼 수 있고, 이에 따라 림프부종의 발병률을 현저하게 낮춰준다. Therefore, the composition according to the present invention can exhibit a good treatment and improvement effect to a desired degree in a short time for a subject already suffering from lymphedema. In addition, it may have an effect of preventing lymphedema in advance in subjects potentially possessing the possibility of having lymphedema (eg, patients undergoing cancer surgery and / or radiation therapy), thereby inciting the incidence of lymphedema. Significantly lower.
이와 같은 본 발명의 조성물은 의약품의 형태로 제공될 수도 있고, 또다르게는 기능성 식품 또는 식품보충제의 형태로 제공될 수도 있다.Such a composition of the present invention may be provided in the form of a pharmaceutical, or alternatively, in the form of a functional food or a food supplement.
도 1은 림프부종 유도 마우스를 부테아 모노스페르마의 추출물로 처리한 경우 림프부종의 크기 변화를 나타낸 그래프이며, 도 2는 시간별로 나누어 나타낸 그래프이다.1 is a graph showing the change in the size of lymph edema when the lymphedema-induced mouse was treated with an extract of butane monosperma, Figure 2 is a graph divided by time.
도 3은 림프부종 유도 마우스를 부테아 모노스페르마의 추출물로 처리한 경우 림프부종의 크기 변화를 카메라로 촬영한 사진이다. 여기서, day 0은 림프부종을 유도하기 위해 외과적 수술이 수행된 날짜이다.Figure 3 is a photograph taken with a camera the size of lymph edema when the lymphedema-induced mouse treated with an extract of buta monosperma. Where day 0 is the date when the surgical operation was performed to induce lymphedema.
도 4는 림프부종의 크기가 가장 큰 값(day 2)을 기준으로 림프부종의 크기를 백분율(%)로 나타낸 그래프이다.4 is a graph showing the size of lymph edema in percentage (%) based on the largest value of lymph edema (day 2).
실시예 1-1: 부테아 모노스페르마 추출물 및 분획물의 준비Example 1-1 Preparation of Butane Monosperma Extract and Fractions
부테아 모노스페르마의 꽃 1g을 10% 효소와 함께 물 10 ml에 침착시켰다. 그 후, 45℃에서 10시간 동안 효소반응시켰다. 이때, 효소로서 알칼라아제(alcalase) 및 카탈라아제(catalase, CAT200)의 혼합물 형태를 사용하거나 또는 카탈라아제(catalase, CAT200)를 단독으로 사용하였다. 1 g of flowers of buta monosperma were deposited in 10 ml of water with 10% enzyme. Thereafter, the enzyme was reacted at 45 ° C. for 10 hours. At this time, a mixture of alcalase and catalase (CATalase, CAT200) was used as the enzyme, or catalase (CATalase, CAT200) was used alone.
그 후, 여과 과정을 통해 불용성 고형물을 제거하고 여과액을 수득하였다. 상기 여과액을 감압농축하여 고체 추출물을 생성하였다. 생성된 고체 추출물에 대해 유기용매를 이용하여 유기층과 물층으로 분획하고, 유기층을 감압농축하여 분획물을 생성하였다. 이때, 유기용매는 에틸 아세테이트, 클로로포름 또는 디클로로메탄을 사용하였다. Thereafter, the insoluble solids were removed through a filtration process to obtain a filtrate. The filtrate was concentrated under reduced pressure to give a solid extract. The resulting solid extract was partitioned into an organic layer and an aqueous layer using an organic solvent, and the organic layer was concentrated under reduced pressure to generate a fraction. At this time, the organic solvent was ethyl acetate, chloroform or dichloromethane.
실시예 1-2: 부테아 모노스페르마 추출물 및 분획물의 준비Example 1-2 Preparation of Buta Monosperma Extract and Fractions
부테아 모노스페르마의 꽃 100mg을 산 촉매와 함께 메탄올 2 ml에 침착시켰다. 그 후, 50℃에서 10시간 동안 산처리반응을 시켰다. 이때, 상기 산 촉매는 10% 1N HCl, 10% 3N HCl, 10% 6N HCl, 10% CH3SO4H, 1% H2SO4, 2.5% H2SO4, 5% H2SO4 또는 10% H2SO4를 사용하였다. 100 mg of the flower of buta monosperma was deposited in 2 ml of methanol with acid catalyst. Thereafter, an acid treatment reaction was performed at 50 ° C. for 10 hours. In this case, the acid catalyst is 10% 1N HCl, 10% 3N HCl, 10% 6N HCl, 10% CH 3 SO 4 H, 1% H 2 SO 4 , 2.5% H 2 SO 4 , 5% H 2 SO 4 or 10% H 2 SO 4 was used.
그 후, 여과 과정을 통해 불용성 고형물을 제거하고 여과액을 수득하였다. 상기 여과액은 감압농축하여 고체 추출물을 생성하였다. 생성된 고체 추출물에 대해 유기용매를 이용하여 유기층과 물층으로 분획하고, 유기층을 감압농축하여 분획물을 생성하였다. 이때, 유기용매는 에틸 아세테이트, 클로로포름 또는 디클로로메탄을 사용하였다. Thereafter, the insoluble solids were removed through a filtration process to obtain a filtrate. The filtrate was concentrated under reduced pressure to give a solid extract. The resulting solid extract was partitioned into an organic layer and an aqueous layer using an organic solvent, and the organic layer was concentrated under reduced pressure to generate a fraction. At this time, the organic solvent was ethyl acetate, chloroform or dichloromethane.
실시예 2: 동물 모델 실험Example 2: Animal Model Experiment
앞서 제조한 부테아 모노스페르마의 추출물 또는 분획물이 림프부종에 대해 어떠한 효과를 나타내는지 입증하기 위하여, 본 발명자들은 마우스에게 외과적으로 림프부종을 유도한 동물 모델을 제작하였다.In order to demonstrate what effect the extracts or fractions of the previously prepared buta monosperma had on lymphedema, we constructed an animal model that surgically induced lymphedema in mice.
구체적으로, 마우스는 Charles River Laboratories(Wilmington, Massachusetts)를 origin으로 하는 Outbred ICR 마우스를 사용하였다. 체중 35±2g의 6주령 수컷 마우스를 구입하여 7일 동안 적응 기간을 거친 후, 마취약(Zoletil50 0.6mg/kg 및 Rompun 0.4mg/kg)을 복강내 주사하여 마취하고, 하지부터 가슴까지 면도하였다. 림프절과 림프관을 염색하기 위한 2% 메틸렌블루 용액 3㎕을 오른쪽 하지 발등에 주사하고, 염색약이 림프관을 따라 잘 퍼질 수 있도록 3분간 염색약 주사 부위를 마사지하였다. 사타구니의 림프절 절제 및 허벅지의 림프관을 차단함에 따른 염증부위의 최소화를 위해 오른쪽 사타구니를 최소로 절개하여 열었다. 이어서, 메틸렌블루로 염색된 superficial inguinal node, popliteal node, deep inguinal node를 순차적으로 제거하고, 우측 하지 허벅지에 염색된 림프관을 인두를 이용하여 차단한 후, 봉합하였다.Specifically, Outbred ICR mice originating from Charles River Laboratories (Wilmington, Massachusetts) were used. Six-week-old male mice weighing 35 ± 2 g were purchased and after 7 days of adaptation, anesthetized with anesthetics (Zoletil50 0.6 mg / kg and Rompun 0.4 mg / kg), anesthetized, and shaved from the lower extremities to the chest. 3 μl of 2% methylene blue solution for staining lymph nodes and lymphatic vessels was injected into the inferior right leg, and the dye injection site was massaged for 3 minutes to allow the dye to spread well along the lymphatic vessels. The right groin was incised and opened minimally to minimize the inflamed area due to lymph node resection of the groin and blockage of the lymphatic vessel of the thigh. Subsequently, superficial inguinal nodes, popliteal nodes, and deep inguinal nodes stained with methylene blue were sequentially removed, and lymphatic vessels stained on the right lower thigh were blocked using a pharynx, and then sutured.
마우스는 정상군(2마리), 대조군(4마리) 및 실험군(3마리)의 총 3개 군으로 분류하였다. 정상군은 마우스에게 외과적 수술을 하지 않은 그룹이다. 실험군은 앞서 실시예 1-2에서 수득한 부테아 모노스페르마의 에틸 아세테이트 분획물을 7일 동안 매일 500 mg/kg(마우스의 체중)의 양으로 경구 투여한 후, 외과적 수술을 통해 마우스의 우측 하지에 림프부종을 유도한 그룹이다. 대조군은 에탄올 버퍼 및 증류수를 7일 동안 경구 투여한 후, 외과적 수술을 통해 마우스의 우측 하지에 림프부종을 유도한 그룹이다.Mice were divided into three groups: normal (2), control (4) and experimental (3). The normal group is a group without surgery on the mice. The experimental group orally administered the ethyl acetate fraction of buta monosperma obtained in Example 1-2 at an amount of 500 mg / kg (mouse of mouse) daily for 7 days, and then surgically performed the right side of the mouse. Lymphedema was induced in the lower extremities. The control group was orally administered with ethanol buffer and distilled water for 7 days, and then surgically induced lymphedema in the right lower extremity of the mouse.
외과적 수술을 수행한 날을 0 day로 설정하였으며, 마우스의 체중 및 사료 섭취량은 매일 한번씩 측정하였으며, 림프부종의 크기는 이틀마다 한번씩 측정하였다. 실험결과는 다음과 같다.The day of surgery was set to 0 day, the body weight and feed intake of the mice were measured once daily, the size of lymph edema was measured once every two days. The experimental results are as follows.
(1) 체중 및 사료 섭취량의 변화(1) changes in body weight and feed intake
외과적 수술을 수행한 날로부터 15일 동안 측정한 결과, 마우스의 체중(g) 및 사료 섭취량(g)은 대조군과 실험군 사이에 유의적인 차이를 나타내지 않았다.As measured for 15 days from the day of surgery, the body weight (g) and feed intake (g) of the mice did not show a significant difference between the control group and the experimental group.
(2) 림프부종의 크기(2) the size of lymphedema
림프부종의 크기는 실험군과 대조군의 마우스에서 발생한 림프부종의 면적(단위 mm2)을 평균값으로 나타내어 도 1 및 도 2에 그래프로 도시하였다. 또한, day 0, day 2, day 4 및 day 6에 촬영한 각 군의 사진을 도 3에 나타내었다.The size of lymph edema is shown graphically in Figs. 1 and 2 showing the mean area (in mm 2 ) of lymph edema in experimental and control mice. In addition, photos of each group taken on day 0, day 2, day 4 and day 6 are shown in FIG.
림프부종은 대조군과 실험군 모두에서 외과적 수술을 수행한지 2일째인 day 2에 가장 큰 크기로 관찰되었다. 그 후에는 대조군과 실험군 모두에서 림프부종의 크기가 감소하였다. Lymphedema was the largest on day 2, the second day after surgery in both control and experimental groups. Thereafter, the size of lymphedema decreased in both control and experimental groups.
대조군과 실험군을 비교하였을 때, day 2에 실험군의 림프부종은 대조군의 림프부종보다 그 크기가 유의적으로 작았다. 이는 림프부종이 발생되기 전 7일 동안 부테아 모노스페르마의 추출물 또는 분획물을 경구투여함에 따라 나타난 결과로서, 본 발명에 따른 조성물이 림프부종의 형성을 억제하고 사전에 예방하는 효과가 있다는 점을 입증하는 것이다.When comparing the control group and the experimental group, on day 2, the lymphedema of the experimental group was significantly smaller than that of the control group. This is a result of oral administration of an extract or fraction of butane monosperma for 7 days before lymphedema develops, suggesting that the composition according to the present invention has the effect of inhibiting and preventing the formation of lymphedema in advance. To prove.
또한, day 4, day 6, day 8에 측정한 실험군의 림프부종과 대조군의 림프부종은 현저한 크기의 차이를 보였으며, 이는 유의적인 정도로 나타났다.In addition, there was a significant difference between the lymphedema of the experimental group and the lymphedema of the control group measured on day 4, day 6, and day 8, which was significant.
(3) 림프부종의 축소 속도(3) reduction rate of lymphedema
실험군과 대조군에서 각각 림프부종의 크기가 가장 큰 값을 기준으로 잡고 시간이 경과함에 따라 림프부종의 크기가 줄어드는 속도를 산출하여 비교하였다. 그 결과, 대조군보다 실험군에서 훨씬 더 빠른 속도로 림프부종의 크기가 줄어든다는 점이 확인되었다(도 4 참조).In the experimental group and the control group, the size of lymph edema was determined based on the largest value, and the rate of lymph edema reduction with time was compared. As a result, it was confirmed that the size of lymph edema decreases much faster in the experimental group than in the control group (see FIG. 4).

Claims (8)

  1. 부테아 모노스페르마의 추출물 또는 분획물을 유효성분으로 포함하는, 림프부종의 치료 또는 예방용 약학 조성물.Buta monosperma extract or fraction comprising as an active ingredient, a pharmaceutical composition for the treatment or prevention of lymphedema.
  2. 제1항에 있어서,The method of claim 1,
    상기 추출물 또는 분획물은 각각 독립적으로 물, 에틸아세테이트, 아세톤, 에탄올, 메탄올, 디클로로메탄, 클로로포름 또는 이들의 혼합물에서 선택된 용매를 이용하여 수득된 것을 특징으로 하는 약학 조성물.The extracts or fractions are each independently obtained using a solvent selected from water, ethyl acetate, acetone, ethanol, methanol, dichloromethane, chloroform or mixtures thereof.
  3. 제1항에 있어서,The method of claim 1,
    상기 추출물 또는 분획물은 부테아 모노스페르마의 꽃으로부터 수득된 것을 특징으로 하는 약학 조성물.The extract or fraction is a pharmaceutical composition, characterized in that obtained from the flowers of buta monosperma.
  4. 제1항에 있어서,The method of claim 1,
    상기 조성물은 암 치료 또는 방사선 치료를 받은 대상체에게 투여되는 것을 특징으로 하는 약학 조성물.The composition is a pharmaceutical composition, characterized in that to be administered to a subject undergoing cancer treatment or radiation treatment.
  5. 부테아 모노스페르마의 추출물 또는 분획물을 유효성분으로 포함하는, 림프부종의 개선 또는 예방용 식품 조성물.Buta monosperma extract or fraction comprising as an active ingredient, a food composition for improving or preventing lymphedema.
  6. 제5항에 있어서,The method of claim 5,
    상기 추출물 또는 분획물은 각각 독립적으로 물, 에틸아세테이트, 아세톤, 에탄올, 메탄올, 디클로로메탄, 클로로포름 또는 이들의 혼합물에서 선택된 용매를 이용하여 수득된 것을 특징으로 하는 식품 조성물.The extracts or fractions are each independently obtained by using a solvent selected from water, ethyl acetate, acetone, ethanol, methanol, dichloromethane, chloroform or mixtures thereof.
  7. 제5항에 있어서,The method of claim 5,
    상기 추출물 또는 분획물은 부테아 모노스페르마의 꽃으로부터 수득된 것을 특징으로 하는 식품 조성물.The extract or fraction is a food composition, characterized in that obtained from the flowers of buta monosperma.
  8. 제5항에 있어서,The method of claim 5,
    상기 조성물은 암 치료 또는 방사선 치료를 받은 대상체에게 투여되는 것을 특징으로 하는 식품 조성물.The composition is a food composition, characterized in that administered to a subject undergoing cancer treatment or radiation treatment.
PCT/KR2017/006160 2016-06-13 2017-06-13 Composition for treating, preventing or reducing edema WO2017217747A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20160073477 2016-06-13
KR10-2016-0073477 2016-06-13

Publications (1)

Publication Number Publication Date
WO2017217747A1 true WO2017217747A1 (en) 2017-12-21

Family

ID=60663666

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2017/006160 WO2017217747A1 (en) 2016-06-13 2017-06-13 Composition for treating, preventing or reducing edema

Country Status (2)

Country Link
KR (1) KR20170140791A (en)
WO (1) WO2017217747A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230149018A (en) 2022-04-19 2023-10-26 (주)에스원바이오 Method, Computer program and System for Providing Customized Treatment Guide using Lymphedema Diagnosis Data

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316166A (en) * 2013-07-17 2013-09-25 宋永心 Tibetan medicine for treating hemorrhoids and preparation method thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101533197B1 (en) * 2014-09-18 2015-07-02 성균관대학교산학협력단 Composition comprising butein for preventing or treating edema

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103316166A (en) * 2013-07-17 2013-09-25 宋永心 Tibetan medicine for treating hemorrhoids and preparation method thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MAHAJAN, R. S. ET AL.: "Evolution of Anti-filarial Therapeutics: An Overview", JOURNAL OF MICROBIOLOGY AND ANTIMICROBIAL AGENTS, vol. 1, no. 1, 2015, pages 16 - 22, XP055450092 *
MAURYA, S. K. ET AL.: "Potential Medicinal Plants for Lymphatic Filariasis: A Review", JOURNAL OF CRITICAL REVIEWS, vol. 1, no. 2, 2015, pages 1 - 6, XP055450091 *
NAUTIYAL, V. ET AL.: "Antiinflammatory Activity of Aqueous Bark Extract of Butea Monosperma (Lam.) Taub", ASIAN JOURNAL OF CHEMISTRY, vol. 23, no. 9, 2011, pages 4219 - 4220, XP055449311 *
SAPKALE, A. P. ET AL.: "Investigation of Anti-inflammatory Activity of Whole Flower Extract of Butea Monosperma by Ex-vivo and in-vitro Techniques and Their Correlation", INTERNATIONAL JOURNAL OF PHARMACY & PHARMACEUTICAL SCIENCES, vol. 5, no. 2, 2013, pages 84 - 86, XP055463201 *

Also Published As

Publication number Publication date
KR20170140791A (en) 2017-12-21

Similar Documents

Publication Publication Date Title
EP3560506A1 (en) Pharmaceutical composition comprising indigo pulverata levis extract or fraction thereof as effective ingredient for preventing or treating inflammatory bowel disease
KR101497276B1 (en) A pharmaceutical composition comprising herbal extracts for prevention and treatment of arthritis and herniation of intervertebral discs
WO2017217747A1 (en) Composition for treating, preventing or reducing edema
CN112370496A (en) Application of effective components of Lycii folium in preparing medicine for preventing or treating hepatic fibrosis
KR20150033797A (en) Pharmaceutical composition for prevention and treatment of atopic skin disease
US8455014B2 (en) Composition comprising Trachelospermi caulis and Pyrola japonica extracts for the treatment and prevention of inflammatory diseases
EP2772264B1 (en) Application of albizzia chinensis extract in preparation of medicine for treatment of gastric ulcer
WO2012108747A2 (en) Composition and cosmetic composition for treating brain cancer comprising helena root extract
KR20220052455A (en) Composition containing an extract of dendropanax morbifera
US9364510B2 (en) Botanical composition and methods of manufacture and use
EP3097920B1 (en) Medical composition comprising stauntonia hexaphylla extract
CN105326700A (en) Rapid skin nourishing agent and application thereof
CN113827587A (en) Application of salvianolic acid A in preparing medicine for preventing thrombotic cerebral ischemia
WO2012108746A2 (en) Composition and cosmetic composition for treating brain cancer comprising rubia cordifolia root extract
EP2043669A2 (en) Compositions and methods for treating and preventing gastro esophageal reflux disease
US8530433B2 (en) Use of icariside II in manufacture of products for preventing or treating male or female sexual dysfunction
KR20020078850A (en) Extract of Angelicae Gigantis Radix having neuroprotective effects and pharmaceutical composition containing the same
CN108938779A (en) A kind of Chinese medicine composition that treating conjunctivitis, preparation method and application
KR20120092267A (en) Composition for treatment of brain cancers and beauty expenses composition comprising extract of pharbitis semen
KR20110008610A (en) A pharmaceutical composition comprising extract of cassia alata as an active ingredient for treatment of vitiligo
CN111728985B (en) A composition containing oviductus Ranae as main ingredient and its application
WO2017217746A1 (en) Composition containing butea monosperma extract or fraction
KR20090023759A (en) Compound with arthritis therapy effect
CN106822152A (en) A kind of pharmaceutical composition and its application
Goswami et al. Andrographis paniculata (Kalmegh): A critical study on medicinal effects

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17813571

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17813571

Country of ref document: EP

Kind code of ref document: A1